US Physical Therapy Approaches Critical Earnings Report

All eyes are on US Physical Therapy (USPH) as the company prepares to release its third-quarter 2025 financial results this Wednesday after market close. This earnings announcement represents a significant test for the healthcare provider, with market participants anticipating strong performance metrics.

Financial analysts project USPH will report earnings of $0.67 per share alongside revenue approximating $194 million for the quarter. These figures will provide crucial insight into whether the company can maintain its current growth trajectory.

This heightened anticipation follows an impressive second-quarter performance where USPH exceeded expectations and subsequently raised its full-year guidance. During that period, the company's adjusted EBITDA increased by $4.7 million to reach $26.9 million.

Expansion Strategy Through Acquisitions

The company's growth has been fueled by strategic acquisitions completed this year. In March, USPH secured a 65% ownership stake in a Wyoming-based clinic. This was followed by an August transaction where the company acquired 60% of a three-clinic practice generating approximately $5.3 million in annual revenue.

Should investors sell immediately? Or is it worth buying US Physical Therapy?

Beyond acquisitions, USPH has developed another significant revenue stream. The industrial injury prevention business segment has now surpassed the $100 million annual revenue threshold, establishing itself as a substantial secondary pillar for the organization.

Potential Medicare Catalyst

Industry observers are monitoring potential regulatory changes that could benefit USPH. After years of reimbursement pressure, the physical therapy sector anticipates Medicare payment rates may increase next year for the first time in several years. Such a development would provide additional tailwinds for the company's financial performance.

Wall Street sentiment appears positive ahead of the earnings release. The consensus rating among analysts stands at "Moderate Buy" with price targets ranging between $104 and $110 per share. JPMorgan initiated coverage in September with an "Overweight" rating and a $110 price target.

The upcoming earnings report will reveal whether USPH can capitalize on these favorable conditions. Beyond the quarterly numbers, investors will closely scrutinize management's commentary regarding future strategic direction and growth initiatives.